

REMARKS

The examiner has deemed the amendment filed October 29, 2003 unresponsive to the Office Action of June 26, 2003 because the sequences in the submitted sequence listing do not correspond to the sequences identified in the specification. This position is respectfully traversed. The sequences in the sequence listing are the same as those in the specification, with the exception that some sequences are presented in the opposite orientation as required by the rules.

The applicant respectfully refers to the Amendment Under 37 C.F.R. 1.116 Expedited Procedure Examining Group 1631, mailed December 11, 2001, a copy of which is enclosed for the convenience of the examiner. The amendment of December 11, 2001 included the addition of sequence identifiers to the brief description of Figures 1A and 1B in the paragraph occurring on page 3, line 18 of the originally filed specification. These amendments included the addition of SEQ ID NOS:12-20 to the description of Figure 1A, and the addition of SEQ ID NOS:21-29 to the description of Figure 1B. This amendment conforms the specification to the substitute sequences listing also filed as part of the December 11, 2001 amendment.

The substitute sequence listing filed December 11, 2001 contains 30 sequences. The sequences represented by SEQ ID NOS: 3-6, 13-20, and 22-29 in the substitute sequence listing represent sequences presented on page 26, lines 22-23, and in Figures 1A and 1B of the originally filed application. These sequences are presented in a 3'→5' orientation in the specification and figures. In order to comply with 37 C.F.R. 1.822(c)(5), which states that all nucleotide sequences in a sequence listing must be presented "in the 5 to 3 direction, from left to right," SEQ ID NOS: 3-6, 13-20, and 22-29 are presented in a 5'→3' orientation in the sequence listing. Thus SEQ ID NOS: 3-6, 13-20, and 22-29 of the substitute sequence listing filed December 11, 2001 must be and are presented in the reverse orientation of the sequences as presented in the specification and figures. The presentation of these sequences in the reverse orientation is discussed in the Remarks section of the amendment mailed December 11, 2001.

Therefore, other than that some sequences in the sequence listing are presented in a different orientation than appears in the specification, the sequences in the sequence listing are the same as those in the specification.



Mark Chee et al.  
Application No.: 08/856,376  
Page 4

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: (650) 326-2400  
Fax: (415) 576-0300  
JOL:adm

60136246 v1